Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 8Lung Neoplasms 6Colorectal Neoplasms 6Neoplasms 5Prostatic Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Ovarian Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Liver Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma 2Wilms Tumor 1Vulvar Neoplasms 1Vaccinia 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Papillary renal cell carcinoma, sporadic 1PIK3CA-Mutated Cancers 1Osteosarcoma 1

Interventions

Gemcitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 8Cisplatin 7pembrolizumab 6Radiation 5Mitomycin 4Fluorouracil 4Cystoscopy 4enfortumab vedotin 3durvalumab 3dehydroftorafur 3avelumab 3Transurethral Resection of Bladder 3Radiotherapy 3Platinum 3Nivolumab 3Mitozytrex 3Cystectomy 31,2-diaminocyclohexaneplatinum II citrate 3ulixertinib 2tremelimumab 2erdafitinib 2atezolizumab 2Paclitaxel 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × atezolizumab × 30 days × Clear all
NCT03289962 2026-05-29

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Genentech, Inc.

Phase 1 Completed
273 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡